Efficacy and Safety of Prolonged-Release Melatonin for Primary Insomnia in Elderly Patientsopen access
- Authors
- Park, Young-Min; Lee, So-Jin; Lee, Jin-Seong; Na, Kyoung-Sae; Kang, Seung-Gul; Lee, Bun-Hee; Yoon, Ho-Kyoung; Kim, Eui-Joong
- Issue Date
- Sep-2023
- Publisher
- Korean Society of Sleep Medicine
- Keywords
- Circadin; Elderly; Insomnia; Melatonin
- Citation
- Chronobiology in Medicine, v.5, no.3, pp.138 - 143
- Journal Title
- Chronobiology in Medicine
- Volume
- 5
- Number
- 3
- Start Page
- 138
- End Page
- 143
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89458
- DOI
- 10.33069/cim.2023.0021
- ISSN
- 2635-9162
- Abstract
- Objective: Insomnia, a prevalent sleep disorder affecting the elderly, necessitates effective and safe treatment options. This study explores the potential of the prolonged-release melatonin (Circadin®) addressing insomnia in elderly patients. Methods: The 8-week prospective observational study involved 115 participants, assessing sleep parameters using the Pittsburgh Sleep Quality Index (PSQI) and WHO-5 Well-being Index. The prolonged-release melatonin (2 mg) was administered nightly, and assessments were conducted at baseline, 4 weeks, and 8 weeks. Results: Both per protocol and last observation carried forward (LOCF) analyses consistently revealed significant improvements in sleep latency, total sleep time, sleep efficiency, and overall well-being. Notably, sleep latency decreased after 4 and 8 weeks, while total sleep time and sleep efficiency increased, reflecting longer and more restful sleep. The WHO-5 Well-being Index exhibited noticeable enhancement. Adverse events, including dizziness and heartburn, were manageable. Despite a high dropout rate, this drug’s potential as an efficacious and safe treatment option for elderly insomnia patients was evident, aligned with prior research. Conclusion: The prolonged-release formulation’s resemblance to the natural circadian rhythm of melatonin release offers advantages over conventional medications. This study contributes to understanding the prolonged-release melatonin’s promise as a valuable therapeutic alternative, encouraging further investigation into its long-term effects and optimal implementation. Copyright © 2023 Korean Academy of Sleep Medicine.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89458)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.